- Home
- ADIL vs NLSP Comparison
ADIL vs NLSP Comparison
Compare ADIL & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADIL
- NLSP
- Stock Information
- Founded
- ADIL 2010
- NLSP 2015
- Country
- ADIL United States
- NLSP Switzerland
- Employees
- ADIL N/A
- NLSP N/A
- Industry
- ADIL Biotechnology: Pharmaceutical Preparations
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- ADIL Health Care
- NLSP Health Care
- Exchange
- ADIL Nasdaq
- NLSP Nasdaq
- Market Cap
- ADIL 6.5M
- NLSP 6.2M
- IPO Year
- ADIL 2018
- NLSP 2021
- Fundamental
- Price
- ADIL $0.96
- NLSP $1.91
- Analyst Decision
- ADIL Strong Buy
- NLSP
- Analyst Count
- ADIL 1
- NLSP 0
- Target Price
- ADIL $8.00
- NLSP N/A
- AVG Volume (30 Days)
- ADIL 86.8K
- NLSP 2.2M
- Earning Date
- ADIL 11-13-2024
- NLSP 10-18-2024
- Dividend Yield
- ADIL N/A
- NLSP N/A
- EPS Growth
- ADIL N/A
- NLSP N/A
- EPS
- ADIL N/A
- NLSP N/A
- Revenue
- ADIL N/A
- NLSP N/A
- Revenue This Year
- ADIL N/A
- NLSP N/A
- Revenue Next Year
- ADIL N/A
- NLSP N/A
- P/E Ratio
- ADIL N/A
- NLSP N/A
- Revenue Growth
- ADIL N/A
- NLSP N/A
- 52 Week Low
- ADIL $0.77
- NLSP $1.73
- 52 Week High
- ADIL $4.17
- NLSP $20.80
- Technical
- Relative Strength Index (RSI)
- ADIL 37.57
- NLSP 41.47
- Support Level
- ADIL $0.99
- NLSP $1.87
- Resistance Level
- ADIL $1.06
- NLSP $2.08
- Average True Range (ATR)
- ADIL 0.06
- NLSP 0.27
- MACD
- ADIL -0.01
- NLSP 0.03
- Stochastic Oscillator
- ADIL 0.00
- NLSP 8.77
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.